Get the Stockscreener App
7.50
0.94%
0.07
Lipocine Inc stock is traded at $7.50, with a volume of 748.
It is up +0.94% in the last 24 hours and down -25.00% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$7.43
Open:
$7.43
24h Volume:
748
Relative Volume:
0.01
Market Cap:
$54.24M
Revenue:
$1.98M
Net Income/Loss:
$-9.63M
P/E Ratio:
-4.2486
EPS:
-1.7653
Net Cash Flow:
$-9.76M
1W Performance:
+2.60%
1M Performance:
-25.00%
6M Performance:
+174.73%
1Y Performance:
+116.14%
1-Day Range:
$7.43
$7.43
1-Week Range:
$6.91
$7.795
52-Week Range:
$2.52
$12.37
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
7.43 | 54.24M | 1.98M | -9.63M | -9.76M | -1.7653 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Gains Recap: Is Lipocine Inc a cyclical or defensive stockQuarterly Performance Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Aug Mood: What is the Moat Score of Lipocine IncMarket Sentiment Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Lipocine (NASDAQ:LPCN) Rating Increased to Hold at Wall Street Zen - MarketBeat
If You Invested $1,000 in Lipocine Inc (LPCN) - Stock Titan
Lipocine price target raised to $11 from $6.75 at Alliance Global - TipRanks
Lipocine Announces 2025 Financial Results and Progress on Postpartum Depression, Epilepsy, and Obesity Drug Pipeline - Minichart
Lipocine Inc. 2025 Annual Report: Innovative Oral Drug Delivery, CNS & Metabolic Pipeline, and R&D Highlights - Minichart
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - The Herald Journal
Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Lipocine 2025 Financial Results: Q4 & Annual PerformanceNews and Statistics - IndexBox
Lipocine: Fourth Quarter Financial Results Overview - Bitget
Lipocine: Q4 Earnings Snapshot - Barchart
Lipocine (NASDAQ: LPCN) 2025 revenue falls to $2M with $9.6M loss - Stock Titan
LPCN: 2025 saw a net loss of $9.6M as revenue fell, with cash runway through Q1 2027 and ongoing R&D focus - TradingView
Lipocine 10-K: Revenue $2.0M, EPS (Basic) $(1.77) - TradingView
LPCN: Pipeline advanced and cash raised, but revenue dropped and net loss widened in 2025 - TradingView
Lipocine Inc expected to post a loss of 61 cents a shareEarnings Preview - TradingView
Is Lipocine Inc affected by consumer sentiment2026 Performance Recap & Weekly Setup with High ROI Potential - baoquankhu1.vn
AI Stocks: Will Lipocine Inc benefit from rate cuts2025 Support & Resistance & Daily Profit Maximizing Tips - baoquankhu1.vn
Lipocine Stock Quote, Share Price, News and Analysis - Longbridge
Lipocine Files Prospectus to Enable $50M Stock Offering - The Globe and Mail
Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World
Lipocine (LPCN) establishes $50M at-the-market common stock sales plan - Stock Titan
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - Nasdaq
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance
Lipocine Files For Common Stock Offering Of Up To $50 MillionSEC Filing - TradingView
LivePerson (NASDAQ: LPCN) increases ATM sales capacity to $50M - Stock Titan
Lipocine (LPCN) Jumps 5.5%: Does the Stock Have More Room to Grow? - Bitget
ETF Watch: Is Lipocine Inc a turnaround storyTreasury Yields & Daily Momentum Trading Reports - baoquankhu1.vn
Can Lipocine Inc. stock beat market expectations this quarterTreasury Yields & Short-Term High Return Ideas - mfd.ru
Lipocine completes patient visits in phase 3 trial for PPD treatment - Investing.com Australia
Lipocine completes patient visits in phase 3 trial for PPD treatment By Investing.com - Investing.com South Africa
Lipocine Completes Phase 3 Trial for Postpartum Depression - TipRanks
Lipocine (NASDAQ: LPCN) files updated corporate investor presentation - Stock Titan
Is Lipocine Inc. stock a buy on dips2025 Key Lessons & Proven Capital Preservation Tips - mfd.ru
Is Lipocine Inc. a potential multi baggerMarket Volume Summary & Low Drawdown Momentum Ideas - mfd.ru
Lipocine Announces Late Breaking Oral Presentation of Data from - GuruFocus
Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 - Finviz
Does Lipocine Inc. stock have upside surprise potential2025 Stock Rankings & Long Hold Capital Preservation Tips - mfd.ru
Why Lipocine Inc. stock is favored by top institutionsJuly 2025 WrapUp & Smart Allocation Stock Reports - mfd.ru
S P Trends: Does Lipocine Inc offer margin of safetyMarket Activity Summary & Short-Term High Return Ideas - baoquankhu1.vn
Lipocine Announces Positive Interim Results for PPD Trial - MSN
Lipocine (LPCN) Price Target Increased by 58.18% to 11.09 - Nasdaq
Market Moves: Can Lipocine Inc ride the EV waveJuly 2025 News Drivers & Precise Swing Trade Alerts - baoquankhu1.vn
EV Market: Is Lipocine Inc a cyclical or defensive stockPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress - Investing.com India
Lipocine completes enrollment in phase 3 trial for PPD treatment By Investing.com - Investing.com South Africa
Lipocine Completes Phase 3 Enrollment for Postpartum Depression Drug - TipRanks
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):